Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26998239 | 1.00 | IRAK4 (0.39) | IRAK4LRRK2MAPK8ROCK2ROCK1 | |
| SCHEMBL26998242 | 0.88 | ACACB (0.37) | IRAK4LRRK2MAPK8ROCK2ROCK1 | |
| SCHEMBL26998139 | 0.82 | ROCK2 (0.37) | LRRK2ROCK2ROCK1 | |
| SCHEMBL26998140 | 0.82 | ROCK2 (0.37) | LRRK2ROCK2ROCK1 | |
| SCHEMBL25423523 | 0.81 | IRAK4 (0.40) | IRAK4ROCK2ROCK1PPARAAKT1 | |
| SCHEMBL25425146 | 0.78 | AKT1 (0.44) | IRAK4AKT1 | |
| SCHEMBL26725208 | 0.77 | ACACB (0.39) | IRAK4ROCK2ROCK1AKT1 | |
| SCHEMBL25424986 | 0.76 | AKT2 (0.39) | IRAK4AKT1 | |
| SCHEMBL26999128 | 0.74 | MCL1 (0.37) | IRAK4ROCK2ROCK1PPARA | |
| SCHEMBL31405167 | 0.71 | ACACB (0.34) | IRAK4ROCK2ROCK1PPARAGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | IRAK4 4006/4885LRRK2 305/4885MAPK8 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.